BEIJING, June 02, 2022 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in providing molecular profiling tests, cancer early detection product development and companion diagnostics, today announced the publication of 10 research findings at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Based on Genetron Health’s patented One-Step™ Seq method and leading products such as Onco PanScan™, the results were intended to contribute to scientific research and clinical practice in full-cycle cancer management.
These studies involved an in-depth analysis of the Chinese population and focused on analyzing the characteristics of genetic mutations and fusion mapping of several types of cancer, including lung cancer and gastric cancer, guiding clinical diagnosis and treatment through molecular characteristics and by predicting the effectiveness of the immune system. checkpoint inhibitors (ICI) by screening potential immunotherapy biomarkers. Integrated with clinical data, these results come from joint studies conducted by Genetron Health with more than 10 leading hospitals and scientific research institutes in China.
“These research results presented at ASCO 2022, all of which are based on patented technology and innovative products from Genetron Health, explore the genomic characteristics of multiple cancer types and the clinical application of the products,” said Dr. Yunfu Hu, medical director of Genetron Health. . “In the future, Genetron Health’s products and technologies will continue to drive the full cycle of cancer patient care and aid in accurate clinical diagnosis and treatment. »
The 10 research findings published by Genetron Health at ASCO 2022 focused primarily on the following three areas:
Helping in gene mutation and fusion mapping explaining cancer pathogenesis and developing personalized therapy
Based on next-generation sequencing (NGS), studies #e20530, #8530, #e15124, #3121 explored the METex14 skipping gene mutation, the coexistence of ALK fusions and other driver mutations, and ROS1 fusions , respectively. The results indicated the characteristics and patterns of gene fusions and the coexistence of driver mutations, with the aim of better explaining the pathogenesis of cancers and further developing the value of personalized drug therapies such as TKIs.
Molecular characteristics guide clinical diagnosis and treatment
Currently, little is known about the molecular characteristics of patients with synchronous multiple primary colorectal cancer (sMPCC) in clinical practice. Adopting immunofluorescence (IHC) and NGS-based Onco PanScan™ technology from Genetron Health, Study #3601 found that high frequencies of mismatch repair deficient (MMR) or microsatellite instability (MSI) in the sMPCCs were significantly higher than those in single primary CRC. Therefore, it is recommended that before receiving treatment, synchronous CCPD patients be screened to identify their MMR or MSI status for each lesion and be divided into three subgroups accordingly. Patients with different MMR or MSI status should be treated with personalized therapies for better management of their disease.
Drug therapy has always been a challenge for gastric cancer. Although HER2-directed therapy and ICI have achieved great success, there is still an urgent need to develop other valid targeted drugs. Study #e16061 retrospectively investigated the relationship between gene fusions and driver mutations, MSI, TMB (tumor mutation burden), and ROR in gastric cancer tissue samples from Chinese patients, indicating that the Targetable fusion testing should be advised for patients whose disease progresses after receiving standard therapy.
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal cancer with a poor prognosis and limited treatment options. Study #4159 adopted Genetron Health’s Onco PanScan™, a deep sequencing panel, to perform comprehensive genomic characterization analysis of 84 Chinese SBA patients, and found that at least 39% of patients in the cohort showed exploitable genetic alterations. The study provided a benchmark for precision diagnosis and treatment, and genomically matched clinical trials.
Screening for potential immunotherapy biomarkers to predict ICI efficacy
By analyzing data from the Cancer Genome Atlas (TCGA) cohorts, the Memorial Sloan Kettering Cancer Center (MSKCC) cohorts and the Genetron Health Chinese cohort, studies #e14536, #e16083, #e14581 explored the loss values of polybromo 1 (PBRM1) function, inactivation of chromatin remodeling complexes and TP53 mutations as potential predictors of ICI efficacy.
About Genetron Investments Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in molecular cancer profiling and leverages advanced technologies in biology molecular and data science to transform cancer treatment. The company has developed a comprehensive oncology portfolio that covers the full spectrum of cancer management, addressing the needs and challenges of early detection, diagnosis and treatment recommendations, as well as monitoring and care. continuations of the disease. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Statements that are not of historical fact, including statements about the company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some instances, forward-looking statements may be identified by words or phrases such as “may”, “will”, “expect”, “anticipate”, “target”, “aim”, “estimate”, ” intends to”, “plans”, “believes”, “potential”, “continues”, “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release speaks as of the date of this press release, and the Company undertakes no obligation to update such information except as required by applicable law.
Contact person for media relations